newsfilter
← Latest News
PR Newswire·

RegeneRx Issues Letter To Stockholders

ROCKVILLE, Md., April 11, 2023 /PRNewswire/ -- RegeneRx Biopharmaceuticals, Inc. (OTCQB:RGRX) ("the Company" or "RegeneRx"), a clinical-stage drug development company focused on tissue protection, repair,